Microburst Vagus Nerve Stimulator (VNS) Therapy Feasibility Study

Epilepsies, Partial Clinical Trial

— Microburst  

Official title:

Microburst VNS Therapy Feasibility Study in Subjects With Refractory Epilepsy

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT03446664
• Other study ID #: LNN001
• Status: Completed
• Phase: N/A
• Start date: February 27, 2018
• Est. completion date: October 27, 2021

Study information

• Verified date: October 2022
• Source: LivaNova
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

Evaluate the initial safety and effectiveness of Microburst VNS stimulation in subjects with refractory epilepsy.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 33
• Est. completion date: October 27, 2021
• Est. primary completion date: July 30, 2021
• Accepts healthy volunteers: No
• Gender: All
• Age group: 12 Years and older

Eligibility

Inclusion Criteria:

1. Clinical diagnosis of medically refractory epilepsy with primary generalized tonic-clonic seizures (limited to 20 subjects) or partial onset seizures including complex partial seizures with or without secondary generalization (limited to 20 subjects).

2. Must be on adjunctive antiepileptic medications.

3. Willing and capable to undergo multiple evaluations with functional magnetic resonance imaging (fMRI), electroencephalogram (EEG) and electrocardiogram (ECG).

4(A) For subjects with partial onset seizures: An average of = 3 countable seizures per month based on seizure diary during the 3 month baseline period and no seizure-free interval greater than 30 days during those 3 months.

4(B) For subjects with PGTCs: Have at least = 3 countable seizures during the 3 month baseline period. Note: Each seizure within a cluster may be counted as separate seizures.

5. 12 years of age or older.

6. Subject is a male or non-pregnant female adequately protected from conception. Females of childbearing potential must use an acceptable method of birth control.

7. Provide written informed consent-assent/Health Insurance Portability and Accountability Act (HIPAA) authorization and self-reported measures with minimal assistance as determined by the investigator.

Exclusion Criteria:

1. Currently using, or are expected to use, short-wave diathermy, microwave diathermy, or therapeutic ultrasound diathermy.

2. A VNS Therapy System implant would (in the investigator's judgment) pose an unacceptable surgical or medical risk for the subject.

3. A planned procedure that is contraindicated for VNS therapy.

4. History of implantation of the VNS Therapy System.

5. Currently receiving treatment from an active implantable medical device.

6. Presence of contraindications to MRI per the MRI subject screening record.

7. Known clinically meaningful cardiovascular arrhythmias currently being managed by devices or treatments that interfere with normal intrinsic heart rate responses (e.g., pacemaker dependency, implantable defibrillator, beta adrenergic blocker medications).

8. History of chronotropic incompetence (commonly seen in subjects with sustained bradycardia [heart rate < 50 bpm]).

9. Cognitive or psychiatric deficit that in the investigator's judgment would interfere with the subject's ability to accurately complete study assessments.

10. History of status epilepticus within 1 year of study enrollment.

11. Dependent on alcohol or narcotic drugs as defined by DSM IV-TR within the past 2 years, based on history. Tests for drug or alcohol use will not be administered.

12. Currently being treated with prescribed medication that contains cannabis or cannabis related substance including recreational use.

13. Any history of psychogenic non-epileptic seizures.

14. Currently participating in another clinical study without LivaNova written approval.

Related Conditions & MeSH terms

• Epilepsies, Partial
• Epilepsy
• Epilepsy, Generalized
• Epilepsy, Tonic-Clonic

Intervention

Device:
• Microburst Stimulation
Implantable generator with new stimulation feature under study to determine the safety and effectiveness of device stimulation on different seizure types.

Locations

Country	Name	City	State
Belgium	Ghent University Hosptial	Ghent
United States	University of Alabama at Birmingham	Birmingham	Alabama
United States	Rush University	Chicago	Illinois
United States	University of Denver Colorado	Denver	Colorado
United States	Duke University	Durham	North Carolina
United States	Northwestern University	Evanston	Illinois
United States	Weil-Cornell Medical College	Ithaca	New York
United States	Mayo Clinic Florida	Jacksonville	Florida
United States	University of Utah	Salt Lake City	Utah

Sponsors (1)

Lead Sponsor	Collaborator
LivaNova

Countries where clinical trial is conducted

United States,  Belgium, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Efficacy Primary Endpoint: Percent change from baseline in seizure frequency	For the primary endpoint, the change in the seizure frequency per month compared to baseline will be evaluated for each subject at follow-up visits month 6 and 12.	Up to 12 months study visit
Primary	Safety Primary Endpoint: Occurrence of stimulation related Adverse Events	Assess stimulation/device related adverse events at follow-up visits month 6 and 12.	Up to 12 months study visit
Secondary	Change from baseline in seizure frequency per month based on seizure diary provided by the sponsor		Up to 12 months study visit
Secondary	Change from baseline in seizure severity	As measured by the Seizure Severity Questionnaire (SSQ) scale (Cramer, 2002).	Up to 12 months study visit
Secondary	Change from baseline in quality of life	As measured by the QOLIE-31-P for adults 18 years and older (Cramer et al.; 1998) and QOLIE-AD-48 for adolescents 12 to 17 years (Cramer et al.; 1999).	Up to 12 months study visit
Secondary	Change from baseline in antiepileptic drug (AED) load	Estimated as the sum of the prescribed daily dose (PDD)/defined daily dose (DDD) ratios for each AED included in the treatment regimen (Deckers et al., 1997), where DDD (WHO ATC/DDD index) corresponds to the assumed average therapeutic daily dose of a drug used for its main indication.	Up to 12 months study visit
Secondary	Suicidality as measured by the Columbia Suicide Severity Rating Scale (C-SSRS)		Up to 12 months study visit
Secondary	All adverse events		Up to 12 months visit